GLA
TVRD

Great Lakes Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Great Lakes Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$115K Buy
+36,236
New +$142K ﹤0.01% 783

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Great Lakes Advisors's TVRD Position: Q1 2026 in Review

Great Lakes Advisors opened a new position in Tvardi Therapeutics (TVRD) in Q1 2026: 36,236 shares worth $115K. The stake represents ﹤0.01% of the portfolio and ranks #783 among its holdings.

67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Great Lakes Advisors held 36,236 shares of Tvardi Therapeutics worth $115K as of Q1 2026.
  • Tvardi Therapeutics was a new Great Lakes Advisors position in Q1 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Great Lakes Advisors's portfolio in Q1 2026, its #783 holding.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Great Lakes Advisors's 13F filing for Q1 2026, filed 12 May 2026.